证券研究报告| 公司动态点评 2025 年 08 月 27 日 凯赛生物（688065.SH） 1H25 公司业绩同比增长，生物基聚酰胺项目持续推进-凯赛生物 2025 半年报点评 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,114 | 2,958 | 3,537 | 4,704 | 5,704 | | 增长率 yoy（%） | -13.4 | 39.9 | 19.6 | 33.0 | 21.2 | | 归母净利润（百万元） | 367 | 489 | 677 | 817 | 1,012 | | 增长率 yoy（%） | -33.8 | 33.4 | 38.4 | 20.7 | 24.0 | | ROE（%） | 2.8 | 3.1 | 4.6 | 5.3 | 6.2 | | EPS 最新摊薄（元） | 0.51 | 0.68 | 0.94 | 1.13 | 1.40 | | P/E（倍） | 105.7 | 79.3 | 57.3 | 47.5 | ...

凯赛生物（ [Table_StockNameRptType] 688065） 公司点评 25Q2 业绩持续增长，生物基 PA 商业化放量在即 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-08-25 | | [Table_BaseData] 收盘价（元） | 51.71 | | 近 12 个月最高/最低（元） | 56.98/32.48 | | 总股本（百万股） | 721 | | 流通股本（百万股） | 583 | | 流通股比例（%） | 80.88 | | 总市值（亿元） | 373 | | 流通市值（亿元） | 302 | [公司价格与沪深 Table_Chart] 300 走势比较 -15% 6% 27% 48% 69% 8/24 11/24 2/25 5/25 凯赛生物 沪深300 [Table_Author] 分析师：王强峰 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 分析师：刘天其 执业证书号：S0010524080003 电话：17321190296 邮 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company reported a revenue of 1.671 billion yuan for H1 2025, reflecting a year-on-year growth of 16% and a net profit of 309 million yuan, up 25% year-on-year [8] - The sales volume of long-chain dicarboxylic acids, particularly sebacic acid, reached a historical high, with the company maintaining a global leading position in this product line [8] - The company is actively building an ecosystem for bio-based polyamide and its composite materials, with several strategic partnerships and projects underway to enhance production capacity and market reach [8] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3.539 billion yuan, with a year-on-year growth rate of 19.6% [7] - The forecasted net profit for 2025 is 648 million yuan, representing a year-on-year increase of 32.4% [7] - The company's gross margin for Q2 2025 was reported at 34.03%, showing a slight increase compared to previous periods [8]

Key Points Summary of Kasei Bio's Conference Call Company Overview - **Company**: Kasei Bio - **Industry**: Biochemical Manufacturing Financial Performance - **Revenue**: 1.671 billion CNY in H1 2025, up 15.68% YoY [2][37] - **Gross Profit**: 565 million CNY, up 25.4% YoY [2][37] - **Net Profit**: 309 million CNY, up 24.74% YoY [2][37] - **Total Assets**: 23.821 billion CNY, up 25.23% from the beginning of the year [2][37] - **Net Assets**: 17.453 billion CNY, up 51.67% from the beginning of the year [37] - **Fundraising**: Completed a private placement raising 5.915 billion CNY [2][37] Business Segments and Developments Long Carbon Chain Dicarboxylic Acids - **Market Demand**: Strong demand for long carbon chain dicarboxylic acids, with plans for timely capacity expansion [2][6] - **Capacities**: The 40,000-ton caproic acid project is nearing full production, with positive sales performance [3][5] Biobased Polyamide - **Collaborations**: Established a task force with China Merchants Group to advance pilot projects in textiles, construction, and renewable energy [2][4] - **Market Adoption**: Brands like Hailan Home have begun using biobased polyamide materials [2][21] Composite Materials - **Product Development**: Progress in composite materials focusing on modern construction, logistics, and renewable energy [2][5] - **Commercialization**: Long carbon chain nylon has entered mass production for commercial vehicle applications [2][9] Battery Shell Project - **Partnership with CATL**: The project in Hefei is progressing with 18 planned production lines, with the first phase consisting of 4 lines [2][7][8] - **Production Capacity**: Expected to produce 410,000 tons of biobased composite materials annually [7] Solar and Energy Storage Solutions - **Supply Chain**: Established supply chains for photovoltaic frames and developed complete solutions for energy storage [11][12] Market and Regulatory Environment - **Export Stability**: Tariff issues have had minimal impact on export business, maintaining stable export ratios [20][21] - **Intellectual Property**: Victory in a European IP lawsuit positively impacts business in the European market [21] Future Outlook - **Expansion Plans**: Plans to expand production capacity for long carbon chain dicarboxylic acids and biobased polyamide [6][38] - **Policy Support**: Anticipated government policies to support biomanufacturing, including tax incentives [19] - **Market Positioning**: Aiming to become a leading supplier in the domestic market with over 50% market share in dicarboxylic acids by year-end [16] Challenges and Strategies - **Market Acceptance**: Challenges in promoting new materials due to customer adaptation to new technologies [34][35] - **Cost Efficiency**: Focus on reducing costs and improving efficiency through technological innovations [17][18] Conclusion Kasei Bio is positioned for growth with strong financial performance, ongoing collaborations, and a focus on innovative biobased materials. The company is navigating market challenges while leveraging regulatory support to enhance its competitive edge in the biochemical manufacturing industry.

Core Viewpoint - The report highlights the financial performance and operational updates of Cathay Biotech for the first half of 2025, showcasing growth in revenue and net profit, alongside advancements in product development and market expansion in the biomanufacturing sector. Financial Performance - The company's operating revenue for the first half of 2025 reached approximately 1.67 billion RMB, representing a 15.68% increase compared to the same period last year [5] - The total profit amounted to approximately 342 million RMB, reflecting a 21.81% increase year-on-year [5] - The net profit attributable to shareholders was approximately 309 million RMB, marking a 24.74% increase compared to the previous year [5] - The company's total assets increased by 25.23% year-on-year, reaching approximately 23.82 billion RMB [5] Business Overview - Cathay Biotech specializes in the research, production, and sales of new bio-based materials, leveraging synthetic biology and biomanufacturing technologies [6] - The company has an annual production capacity of 115,000 tons for bio-based long-chain dicarboxylic acids, with ongoing projects to expand production capabilities [6] - The bio-based diamine production capacity is 50,000 tons annually, primarily used for producing bio-based polyamides [6] - The company is also developing bio-based nitrogen-containing heterocyclic compounds, which are expected to replace traditional petroleum-based products [6] Industry Context - The biomanufacturing industry is gaining traction due to increasing environmental concerns and the need for sustainable alternatives to fossil fuels [7] - The Chinese government has initiated several policies to promote the development of the bio-economy, including the integration of biotechnology and information technology [8] - The industry is positioned as a strategic emerging sector, with a focus on innovation and sustainability, aiming to achieve competitive parity with fossil-based products by 2025 [8]

Fundraising Overview - The company raised a total of RMB 5,560,621,023.10 from its initial public offering in 2019, after deducting underwriting and advisory fees, resulting in a net amount of RMB 5,279,993,815.60 [1] - In 2023, the company raised RMB 5,918,968,112.35 from a targeted issuance of A-shares, with a net amount of RMB 5,914,724,993.63 after deducting related fees [2] Fund Utilization and Balance - For the 2019 IPO, the net amount raised was RMB 529,407.39 million, with total project investments amounting to RMB 542,500.59 million, resulting in a balance of RMB 15,411.90 million as of the end of the reporting period [3] - In 2023, the net amount raised was RMB 591,750.40 million, with total project investments reaching RMB 592,079.80 million, indicating a balance of RMB 329.40 million [3] Fund Management Practices - The company has established a dedicated management system for the raised funds, adhering to relevant laws and regulations, and has implemented a special account storage system for the funds [6][10] - The company signed multiple tripartite supervision agreements with banks and underwriters to ensure proper management and usage of the raised funds [7][10] Fund Storage Status - As of June 30, 2025, the special accounts for the 2019 IPO have been fully utilized and closed [10] - The special accounts for the 2023 targeted issuance are also set to be closed following the completion of the relevant projects [11] Actual Use of Funds - The company has reported that the funds raised have been utilized in accordance with the planned investment projects, with detailed usage outlined in attached tables [12][15] - Any surplus funds from the projects have been permanently allocated to supplement working capital for daily operations [12][15]

Core Insights - Synthetic polyamides are crucial industrial materials with applications in automotive, oil pipelines, electronics, sports equipment, and medical industries, with a global market size exceeding 100 billion RMB [1] - China is the largest consumer market for polyamide materials, with an annual demand reaching several million tons [1] - Polyamide 6 (PA6) and Polyamide 66 (PA66) account for over 90% of the total production [1] - The synthesis of polyamides begins with specific monomers, including lactams, dicarboxylic acids, and diamines, which contribute to the diversity of polyamide types and properties [1] - There is a growing interest in bio-based polyamides, such as PA1010, PA11, PA610, and PA410, driven by advancements in biotechnology [1] - Challenges in chemical production of core monomers include harsh conditions and low reaction efficiency, leading to a focus on developing dicarboxylic acids and diamines through synthetic biology [1] Research and Development - Professor Wang Dan's team at Chongqing University is dedicated to the biosynthesis of key polyamide monomers, including pentamethylenediamine, δ-valerolactam, and 5-aminovaleric acid [2] - The team collaborates with various companies, including Yantai Wanhua Chemical, Guangdong Kingfa Technology, Chongqing Wankai New Materials, and PetroChina [2] Industry Events - Professor Wang Dan will present at the SynBioCon 2025 conference from August 20-22 in Ningbo, Zhejiang, focusing on "Biomanufacturing of Polyamide Material Monomers and Applications of Green Low-Carbon Materials" [3] - The conference will showcase multiple technological achievements, including bio-based chemicals and materials, and L-piperidine carboxylic acid [3] - The SynBioCon 2025 will explore key directions in green chemistry and biomanufacturing, aiming to replace petroleum-based raw materials with sustainable alternatives [9]

Group 1 - Synthetic polyamides are important industrial materials with applications in automotive manufacturing, oil pipelines, electronics, sports equipment, and medical industries, with a global market size exceeding 100 billion RMB [1] - China is the largest consumer market for polyamide materials, with an annual demand reaching several million tons [1] - Polyamide 6 (PA6) and Polyamide 66 (PA66) account for over 90% of the total production of polyamides [1] Group 2 - The production of core monomers for polyamides through chemical methods faces challenges such as harsh conditions and low reaction efficiency [2] - The development of biotechnological methods for synthesizing key chemical monomers like dicarboxylic acids and diamines is gaining industry attention [2] - Professor Wang Dan's team at Chongqing University is focused on the biosynthesis of key polyamide monomers, collaborating with various companies [2][4] Group 3 - Professor Wang Dan will present at the SynBioCon 2025 conference, discussing the biomanufacturing of polyamide materials and their applications in green low-carbon materials [3] - Multiple technological achievements related to biobased chemicals and materials will be showcased at the conference [4] Group 4 - The SynBioCon 2025 conference will focus on five key areas, including green chemistry and biomanufacturing, aiming to explore alternatives to petroleum-based raw materials [8]

Core Viewpoint - The article discusses the establishment and investment plans of招商凯赛生物材料 (Zhongshan Kaisa Biochemical Materials) in the production of bio-based composite materials, highlighting its commitment to green and sustainable manufacturing practices. Group 1: Project Overview - 招商凯赛生物材料 plans to invest 468.5 million yuan in an annual production project of 41,000 tons of bio-based composite materials, which includes 20,000 tons/year of composite products, 3,000 tons/year of photovoltaic frame products, and 18,000 tons/year of construction template products. The project is scheduled to be built from April 2025 to December 2026 [1]. - The bio-based polyamide is produced from renewable biomass resources, utilizing biological, chemical, and physical methods to create monomers for synthetic polyamide, resulting in a polymer material that is green, environmentally friendly, and renewable [1]. Group 2: Company Background - 招商凯赛生物材料 was established in December 2024, funded by Shanghai Kaisa Biotechnology Co., Ltd. The company focuses on the research and production of bio-based polyamide resins for composite product processing, emphasizing the green, low-carbon, and energy-saving characteristics of its products [2]. - The company has been actively developing new materials such as bio-based long-chain polyamides and high-temperature polyamides, while also promoting innovative projects like continuous fiber-reinforced bio-based polyamide composites and the utilization of agricultural waste [2]. Group 3: Collaboration and Future Plans - In May 2024, Hefei City signed a tripartite cooperation agreement with 招商创科 and 凯赛生物 to advance the development of the bio-manufacturing industry, with a total investment of approximately 5 billion yuan planned for the project in two phases [2]. - The first phase involves an investment of 1 billion yuan, which includes the composite project and bio-based polyamide modification project, while the second phase plans to invest 4 billion yuan, focusing on further capacity expansion and collaborations with companies like 宁德时代 and 韩国3P公司 [2].

Core Viewpoint - The article discusses the establishment and growth of Hefei Hydrogen He, a joint venture focused on bio-based materials, highlighting its strategic partnerships and financial performance of its parent company, Kaisa Bio [1][5]. Company Overview - Hefei Hydrogen He was registered on April 9, 2025, in the Hefei area of the China (Anhui) Free Trade Pilot Zone, with a registered capital of 20 million RMB, where Kaisa Bio holds a 55% stake [1]. - The legal representative of Kaisa Bio is Zhang Hongguang, who has been the Vice President since August 2019 [2]. Shareholding Structure - Kaisa Bio holds 55% of Hefei Hydrogen He, contributing 11 million RMB, while 3P.COM Corporation from South Korea holds 45%, contributing 9 million RMB [3]. Strategic Partnerships - In January 2024, Kaisa Bio signed an agreement with 3P.COM to establish a joint venture focusing on thermoplastic bio-based polyamide composite materials for hydrogen storage and transportation, urban air mobility, and wind turbine blades [3]. - Kaisa Bio has also established several other companies, including a joint venture with Ningde Times and Calai Composites, focusing on bio-based composite materials for battery casings and automotive parts [4]. Financial Performance - Kaisa Bio reported a total revenue of 2.958 billion RMB for 2024, marking a year-on-year increase of 39.91%, and a net profit of 489 million RMB, up 33.41% from the previous year [5]. Product Capacity and Sales - Kaisa Bio's total production capacity for various bio-based materials reached nearly 300,000 tons by the end of 2024, with specific capacities as follows: - Bio-based long-chain dicarboxylic acid: 115,000 tons [6] - Bio-based pentamethylenediamine: 50,000 tons [7] - Bio-based polyamide: 100,000 tons [8] - Bio-based continuous fiber thermoplastic composite materials [9]. - The main revenue sources for 2024 were long-chain dicarboxylic acid products, generating 2.670 billion RMB, and bio-based polyamide products, generating 144 million RMB [9]. Application Expansion - In March 2024, Kaisa Bio signed a cooperation agreement with China Merchants Highway and China Merchants Jinling to establish a joint laboratory for bio-based new materials, aiming to enhance performance and reduce costs in highway and green energy materials [11]. - Kaisa Bio provided low-carbon, high-performance composite materials for Qingdao Honghu Aviation Technology's RAP-AT1 active temperature-controlled container, which has entered commercial use [12].